Oral Anticoagulants — MCQs
Which of the following drugs is a direct inhibitor of clotting factor Xa?
The anticoagulant activity of warfarin can be reduced by all of the following except.
What is the treatment for Dabigatran toxicity?
Which of the following is an oral direct thrombin inhibitor?
Oral factor Xa inhibitor is:
A patient is on warfarin therapy. All of the following drugs increase the risk of bleeding with warfarin except?
Which of the following is a parenteral direct thrombin inhibitor?
Which of the following is NOT a function of glycosaminoglycans?
Which of the following drugs is used for treatment of cancer associated thromboembolism?
To replenish the inventory, blood banks routinely issue blood packets which are close to the expiry date. Which of the following will be the closest to expiry date, according to the anticoagulant used and the method of storage of the packet:
Oral Anticoagulants Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following drugs is a direct inhibitor of clotting factor Xa?
- A. Argatroban
- B. Fondaparinux
- C. Apixaban (Correct Answer)
- D. Aspirin
Explanation: ***Apixaban*** - Apixaban is an **oral direct factor Xa inhibitor**, which means it directly binds to and inactivates factor Xa. - This inhibition prevents the conversion of **prothrombin to thrombin**, thereby disrupting the coagulation cascade. *Argatroban* - Argatroban is a **direct thrombin inhibitor** (DTI), meaning it selectively binds to and inhibits thrombin (factor IIa). - It is often used in cases of **heparin-induced thrombocytopenia (HIT)** due to its non-heparin-based mechanism of action. *Fondaparinux* - Fondaparinux is an **indirect factor Xa inhibitor** that binds to antithrombin, thereby enhancing antithrombin's ability to inactivate factor Xa. - It does not directly bind to factor Xa itself, but rather potentiates the action of a natural anticoagulant. *Aspirin* - Aspirin is an **antiplatelet agent** that inhibits cyclooxygenase (COX-1), thereby reducing the production of thromboxane A2. - This mechanism primarily inhibits **platelet aggregation** and adhesion, rather than directly inhibiting a clotting factor in the coagulation cascade.
Question 2: The anticoagulant activity of warfarin can be reduced by all of the following except.
- A. Aspirin (Correct Answer)
- B. Rifampin
- C. Vitamin K
- D. Carbamazepine
Explanation: ***Aspirin*** - **Aspirin** does NOT reduce warfarin's anticoagulant activity; instead, it increases the risk of bleeding through a synergistic effect. - Aspirin inhibits platelet aggregation via **cyclooxygenase-1 (COX-1)** inhibition, preventing thromboxane A2 formation, which is a different mechanism from warfarin's inhibition of vitamin K-dependent clotting factors. - When combined with warfarin, aspirin **potentiates** the overall antithrombotic effect and increases bleeding risk. *Carbamazepine* - **Carbamazepine** is a potent inducer of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - By increasing warfarin metabolism, it **reduces** warfarin's plasma concentrations and decreases its anticoagulant effect. - Patients on this combination may require higher warfarin doses to maintain therapeutic INR. *Rifampin* - **Rifampin** is one of the most potent inducers of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - It significantly increases warfarin metabolism, leading to **reduced** plasma concentrations and diminished anticoagulant effect. - This interaction often necessitates substantial increases in warfarin dosage. *Vitamin K* - **Vitamin K** is the direct antagonist of warfarin's mechanism of action. - Warfarin inhibits vitamin K epoxide reductase, preventing the regeneration of active vitamin K needed for synthesis of clotting factors II, VII, IX, and X. - Administration of vitamin K **reverses** warfarin's anticoagulant effect by bypassing the inhibited enzyme and restoring clotting factor production.
Question 3: What is the treatment for Dabigatran toxicity?
- A. Protamine sulphate
- B. Andexanet alfa
- C. Idarucizumab (Correct Answer)
- D. Argatroban
Explanation: ***Idarucizumab*** - **Idarucizumab** is a specific humanized monoclonal antibody fragment (Fab) that directly binds to dabigatran and its metabolites, effectively **reversing its anticoagulant effects**. - It is indicated for patients requiring urgent reversal of dabigatran's anticoagulant effects due to life-threatening or uncontrolled bleeding, or for emergency surgery/urgent procedures. *Protamine sulphate* - **Protamine sulphate** is used to reverse the anticoagulant effects of **heparin** and low molecular weight heparins, but it is ineffective against direct oral anticoagulants like dabigatran. - Its mechanism involves forming a stable ion pair with heparin, neutralizing its activity. *Andexanet alfa* - **Andexanet alfa** is a recombinant modified human factor Xa (FXa) decoy protein used to reverse the anticoagulant activity of **FXa inhibitors** (e.g., rivaroxaban, apixaban). - It does not bind to or reverse the effects of direct thrombin inhibitors like dabigatran. *Argatroban* - **Argatroban** is a **direct thrombin inhibitor** (similar mechanism of action to dabigatran) and is used as an anticoagulant, particularly in patients with heparin-induced thrombocytopenia. - It would worsen dabigatran toxicity rather than treat it, as both drugs inhibit thrombin.
Question 4: Which of the following is an oral direct thrombin inhibitor?
- A. Dabigatran (Correct Answer)
- B. Lepirudin
- C. Rivaroxaban
- D. Warfarin
Explanation: ***Dabigatran*** - **Dabigatran** is the correct answer because it is an **oral direct thrombin inhibitor (DTI)**, meaning it directly inhibits thrombin (factor IIa) to prevent clot formation. - It is one of the **novel oral anticoagulants (NOACs)**, used for conditions like atrial fibrillation and venous thromboembolism. *Lepirudin* - **Lepirudin** is a **direct thrombin inhibitor**, but it is administered **intravenously**, not orally. - It is typically used for **heparin-induced thrombocytopenia (HIT)** when heparin is contraindicated. *Rivaroxaban* - **Rivaroxaban** is an **oral anticoagulant**, but it is a **direct factor Xa inhibitor**, not a direct thrombin inhibitor. - This drug prevents the conversion of prothrombin to thrombin by inhibiting factor Xa. *Warfarin* - **Warfarin** is an **oral anticoagulant**, but it acts as a **vitamin K antagonist (VKA)**, inhibiting the synthesis of coagulation factors II, VII, IX, and X. - It does not directly inhibit thrombin, but rather reduces the production of thrombin precursors.
Question 5: Oral factor Xa inhibitor is:
- A. Bivalirudin
- B. Rivaroxaban (Correct Answer)
- C. Dabigatran
- D. Fondaparinux
Explanation: ***Rivaroxaban*** - **Rivaroxaban** is a direct oral anticoagulant (DOAC) that specifically inhibits **factor Xa**, preventing thrombin generation and clot formation. - It is administered **orally** and is widely used for preventing and treating venous thromboembolism and stroke in atrial fibrillation. *Bivalirudin* - **Bivalirudin** is a **direct thrombin inhibitor** (DTI), not a factor Xa inhibitor. - It is administered **intravenously**, primarily used in percutaneous coronary interventions. *Dabigatran* - **Dabigatran** is an **oral direct thrombin inhibitor** (DTI), which directly inhibits thrombin (factor IIa). - It does not inhibit factor Xa; its mechanism of action is distinct from that of factor Xa inhibitors. *Fondaparinux* - **Fondaparinux** is an **indirect factor Xa inhibitor** that requires antithrombin for its anticoagulant activity. - It is administered **subcutaneously**, distinguishing it from oral factor Xa inhibitors like rivaroxaban.
Question 6: A patient is on warfarin therapy. All of the following drugs increase the risk of bleeding with warfarin except?
- A. Isoniazid
- B. Amiodarone
- C. Carbamazepine (Correct Answer)
- D. Cimetidine
Explanation: ***Carbamazepine*** - Carbamazepine **induces cytochrome P450 enzymes**, specifically **CYP3A4** and **CYP2C9**, which are responsible for warfarin metabolism. - This induction leads to a **faster metabolism of warfarin**, thus **decreasing its anticoagulant effect** and thereby reducing the risk of bleeding. *Isoniazid* - Isoniazid is an **inhibitor of cytochrome P450 enzymes**, primarily **CYP2C9**, which metabolizes the more potent S-warfarin isomer. - This inhibition **decreases warfarin metabolism**, leading to **increased anticoagulant effect** and higher risk of bleeding. *Amiodarone* - Amiodarone is a potent **inhibitor of cytochrome P450 enzymes**, significantly **CYP2C9** and **CYP3A4**. - It leads to a **reduced metabolism of warfarin**, causing **elevated INR** and an increased risk of bleeding. *Cimetidine* - Cimetidine is a known **inhibitor of various cytochrome P450 enzymes**, particularly **CYP1A2**, **CYP2C9**, and **CYP3A4**. - Its inhibitory action on warfarin metabolism results in **higher warfarin levels** and an **increased risk of bleeding**.
Question 7: Which of the following is a parenteral direct thrombin inhibitor?
- A. Ximelagatran
- B. Dabigatran
- C. Argatroban (Correct Answer)
- D. Heparin
Explanation: ***Argatroban*** - **Argatroban** is a **synthetic direct thrombin inhibitor** administered exclusively via **intravenous infusion**, making it a parenteral drug. - It does not require antithrombin for its action and is primarily used in patients with **heparin-induced thrombocytopenia (HIT)**. *Ximelagatran* - **Ximelagatran** was an **oral direct thrombin inhibitor** but was withdrawn from the market due to concerns about severe **liver toxicity**. - As an oral drug, it is not a parenteral medication. *Dabigatran* - **Dabigatran** is a **direct thrombin inhibitor** that is administered **orally** in capsule form (as dabigatran etexilate, a prodrug). - Therefore, it is not a parenteral medication. *Heparin* - **Heparin** is an **indirect thrombin inhibitor** because it requires binding to **antithrombin** to exert its anticoagulant effect. - Although administered parenterally, its mechanism of action is indirect.
Question 8: Which of the following is NOT a function of glycosaminoglycans?
- A. Lubrication of joints
- B. Wound healing process
- C. Anticoagulant activity
- D. Transport of lipids in the bloodstream (Correct Answer)
Explanation: ***Transport of lipids in the bloodstream*** - Glycosaminoglycans (GAGs) generally do not play a direct role in the **transport of lipids** in the bloodstream. Lipid transport is primarily mediated by **lipoproteins** (e.g., chylomicrons, VLDL, LDL, HDL). - While some GAGs might interact with lipoproteins in the extracellular matrix, their fundamental role is not lipid transport but rather structural and signaling functions. *Lubrication of joints* - This is a well-established function of GAGs, particularly **hyaluronic acid**, which contributes to the **viscoelastic properties of synovial fluid**, reducing friction in joints. - Hyaluronic acid helps maintain the **hydration** and **shock-absorbing capacity** of articular cartilage. *Wound healing process* - Glycosaminoglycans, especially **hyaluronic acid** and **heparin sulfate**, are crucial in **wound healing** processes, where they modulate inflammation, cell migration, and tissue remodeling. - They provide a **scaffold for cell proliferation** and differentiation in the wound bed. *Anticoagulant activity* - **Heparin**, a highly sulfated glycosaminoglycan, is a potent **anticoagulant** that works by activating **antithrombin III**, thereby inhibiting various coagulation factors like thrombin. - Other GAGs, like **heparan sulfate** found on cell surfaces, also exhibit mild anticoagulant properties.
Question 9: Which of the following drugs is used for treatment of cancer associated thromboembolism?
- A. Direct factor Xa inhibitors
- B. Warfarin
- C. Anti-thrombin III inhibitors
- D. LMW heparin (Correct Answer)
Explanation: ***LMW heparin*** - **Low molecular weight heparin (LMWH)** is the **preferred anticoagulant for cancer-associated thrombosis** due to its superior efficacy. - It has a more predictable pharmacokinetic profile compared to unfractionated heparin and is administered subcutaneously. *Direct factor Xa inhibitors* - While effective for general venous thromboembolism (VTE) treatment, some direct oral anticoagulants (DOACs) like factor Xa inhibitors (e.g., rivaroxaban, apixaban) may be considered but have shown mixed results in comparative studies with LMWH for cancer patients, especially those with gastrointestinal cancers, presenting a **higher risk of major bleeding**. - **LMWH** remains the **first-line choice**, especially in patients with active cancer, given the evidence for its greater efficacy and safety profile in this specific population. *Warfarin* - **Warfarin** is generally **not recommended** as a first-line treatment for cancer-associated thromboembolism due to its **drug interactions**, need for frequent monitoring (INR), and slower onset of action. - Patients with cancer often have fluctuating nutritional status, hepatic dysfunction, and receive other medications that can significantly impact warfarin's effectiveness and safety. *Anti-thrombin III inhibitors* - **Antithrombin III inhibitors** (e.g., antithrombin concentrate) are primarily used in specific conditions like **hereditary antithrombin deficiency** or in cases of heparin resistance. - They are **not a standard treatment** for cancer-associated thromboembolism in the general population of cancer patients.
Question 10: To replenish the inventory, blood banks routinely issue blood packets which are close to the expiry date. Which of the following will be the closest to expiry date, according to the anticoagulant used and the method of storage of the packet:
- A. ACD, 14 days
- B. SAGM, 25 days with irradiation (Correct Answer)
- C. CPDA, 27 days
- D. SAGM, 35 days
Explanation: ***SAGM, 25 days with irradiation*** - **SAGM** (Saline-Adenine-Glucose-Mannitol) is an additive solution that extends the storage life of red blood cells significantly. - While SAGM usually allows for storage up to **42 days**, if the blood is **irradiated**, the shelf life is reduced to **28 days from collection or 14 days from irradiation, whichever is sooner**. Given the options, 25 days with irradiation falls within this reduced shelf life, making it the closest to expiry among the provided choices (implying the Irradiation was done earlier). *ACD, 14 days* - **ACD** (Acid Citrate Dextrose) is an older anticoagulant primarily used for apheresis products. - Red blood cells collected with ACD typically have a maximum storage duration of **21 days**. While 14 days is within this, other anticoagulant-additive combinations offer longer storage, and this option is not the closest to expiry when considering the maximum allowed. *CPDA, 27 days* - **CPDA** (Citrate Phosphate Dextrose Adenine) provides a standard shelf life of **35 days** for red blood cells. - While 27 days represents blood that has been stored for a significant period, it still has 8 more days until its maximum expiry, making it less "close to expiry" than the irradiated SAGM option which would expire sooner. *SAGM, 35 days* - **SAGM** (Saline-Adenine-Glucose-Mannitol) allows for the storage of red blood cells for up to **42 days** from collection. - At 35 days, a unit stored in SAGM still has 7 days until its maximum expiry date (if not irradiated), making it less "close to expiry" than a unit that had been irradiated.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free